HAE

Haemonetics Corp.

Healthcare


Presented:03/22/2021
Price:$115.77
Cap:$5.88B
Current Price:$75.19
Cap:$3.85B

Presented

Date03/22/2021
Price$115.77
Market Cap$5.88B
Ent Value$6.22B
P/E Ratio54.83x
Book Value$14.15
Div Yield0%
Shares O/S50.82M
Ave Daily Vol380,783
Short Int2.65%

Current

Price$75.19
Market Cap$3.85B
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following business segments: Plasma, Blood Center and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. The Hospital segment provides heomostasis management, cell salvage and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.

Publicly traded companies mentioned herein: CSL Limited (CSL AU), Grifols SA (GRFS), Fresenius Medical Care AG & Co (FMS), Haemonetics Corporation Inc (HAE)

Highlights

The presenter is long shares of Haemonetics Corporation Inc (HAE) based on plasma collection volumes recovering post-COVID-19, the commercialization of two new product cycles that can drive substantial pricing growth, and the opportunity for the company to conduct more bolt-on M&A. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.